KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medtronic (MDT) Share-based Compensation (2016 - 2026)

Medtronic's Share-based Compensation history spans 13 years, with the latest figure at $94.0 million for Q1 2026.

  • For Q1 2026, Share-based Compensation fell 4.08% year-over-year to $94.0 million; the TTM value through Jan 2026 reached $451.0 million, up 4.88%, while the annual FY2025 figure was $429.0 million, 9.16% up from the prior year.
  • Share-based Compensation for Q1 2026 was $94.0 million at Medtronic, down from $182.0 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $182.0 million in Q4 2025 and bottomed at $62.0 million in Q3 2022.
  • The 5-year median for Share-based Compensation is $86.0 million (2025), against an average of $99.4 million.
  • The largest YoY upside for Share-based Compensation was 20.0% in 2022 against a maximum downside of 10.14% in 2022.
  • A 5-year view of Share-based Compensation shows it stood at $137.0 million in 2022, then rose by 6.57% to $146.0 million in 2023, then grew by 8.9% to $159.0 million in 2024, then grew by 14.47% to $182.0 million in 2025, then crashed by 48.35% to $94.0 million in 2026.
  • Per Business Quant, the three most recent readings for MDT's Share-based Compensation are $94.0 million (Q1 2026), $182.0 million (Q4 2025), and $86.0 million (Q3 2025).